Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial -

[11] Bellmunt J(2019)Early lesion detection with (18)F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer Eur J Nucl Med Mol Imaging 46 1911-1918

[12] Bolla M(2015)Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer Mol Imaging Biol 17 575-584

[13] Briers E(2018)(68)Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review World J Urol 36 519-527

[14] Cumberbatch MG(2020)(68)Ga-PSMA I&T PET/CT for primary staging of prostate cancer Eur J Nucl Med Mol Imaging 47 168-177

[15] De Santis M(2016)Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy Eur Urol 69 393-396

[16] Hovels AM(2018)Prostate specific membrane antigen targeted (18)F-DCFPyL positron emission tomography/computerized tomography for the preoperative staging of high risk prostate cancer: results of a prospective, phase II, single center study J Urol 199 126-132

[17] Heesakkers RA(2013)Clinicians are right not to like Cohen’s kappa BMJ. 346 f2125-1877

[18] Adang EM(2018)Quantitative oncology molecular analysis suite: ACCURATE J Nucl Med 59 1753-574.e24

[19] Jager GJ(2010)Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer J Nucl Med 51 1870-557

[20] Strum S(2019)68Ga-PSMA PET/CT: does it predict adverse pathology findings at radical prostatectomy? Urol Oncol 37 574.e19-196

[11] Bellmunt J(2019)Early lesion detection with (18)F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer Eur J Nucl Med Mol Imaging 46 1911-1918

[12] Bolla M(2015)Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer Mol Imaging Biol 17 575-584

[13] Briers E(2018)(68)Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review World J Urol 36 519-527

[14] Cumberbatch MG(2020)(68)Ga-PSMA I&T PET/CT for primary staging of prostate cancer Eur J Nucl Med Mol Imaging 47 168-177

[15] De Santis M(2016)Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy Eur Urol 69 393-396

[16] Hovels AM(2018)Prostate specific membrane antigen targeted (18)F-DCFPyL positron emission tomography/computerized tomography for the preoperative staging of high risk prostate cancer: results of a prospective, phase II, single center study J Urol 199 126-132

[17] Heesakkers RA(2013)Clinicians are right not to like Cohen’s kappa BMJ. 346 f2125-1877

[18] Adang EM(2018)Quantitative oncology molecular analysis suite: ACCURATE J Nucl Med 59 1753-574.e24

[19] Jager GJ(2010)Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer J Nucl Med 51 1870-557

[20] Strum S(2019)68Ga-PSMA PET/CT: does it predict adverse pathology findings at radical prostatectomy? Urol Oncol 37 574.e19-196